{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:12:10Z","timestamp":1789049530334,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The association of immunocompromised states with pediatric COVID-19 outcomes remains unclear. This study assessed COVID-19 severity in hospitalized children with and without immunocompromising conditions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Children &lt;17 years hospitalized in Canada for COVID-19 (April 2020\u2013December 2022) were identified through the Canadian Paediatric Surveillance Program and Canadian Immunization Monitoring Program, ACTive. Immunocompromised children (IC) were those with immune-compromising conditions and\/or on immunosuppressive treatment. Severe COVID-19 was defined as intensive care unit admission, ventilator\/hemodynamic support, organ complications or death. Adjusted risk ratios (aRR) for severe COVID-19 among IC versus nonimmunocompromised children (non-IC) were calculated using Poisson regression, adjusting for age, sex, other underlying conditions, SARS-CoV-2 lineage and vaccination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 3218 children hospitalized for COVID-19, 354 (11.0%) were IC. IC were older [median age 6.7 years (interquartile range = 3.6\u201311.8)] than non-IC [1.2 years (interquartile range = 0.2\u20134.8); <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001]. IC experienced less respiratory distress than non-IC (20.9% vs. 48.1%). Severe COVID-19 (14.1% vs. 29.0%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), respiratory support (16.1% vs. 35.6%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and intensive care unit admission (5.9% vs. 17.4%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) were less frequent in IC. IC were less likely to have severe COVID-19 than non-IC [aRR = 0.46 (95% confidence interval [CI]: 0.32\u20130.65)], with both immunodeficiency [aRR = 0.53 (95% CI: 0.39\u20130.73)] and immunosuppression [aRR = 0.40 (95% CI: 0.23\u20130.73)] subcategories independently associated with reduced risk. Compared to non-IC with other conditions, IC had a lower risk of severe COVID-19 [aRR = 0.35 (95% CI: 0.25-0.47)].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Hospitalized IC exhibited a lower risk of severe COVID-19 than non-IC, potentially reflecting lower admission thresholds for IC with respiratory infections.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004856","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:04:25Z","timestamp":1748538265000},"page":"965-972","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Severity of COVID-19 in Hospitalized Immunocompromised Children Across Canada"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-0612","authenticated-orcid":false,"given":"Costanza","family":"Di Chiara","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Department of Women\u2019s and Children\u2019s Health, University of Padova, Padova, Italy"},{"name":"Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilmann","family":"Schober","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Infectious Diseases, Montreal Children\u2019s Hospital, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Pediatrics, Dr von Hauner Children\u2019s Hospital, Ludwig-Maximilians-University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Farrar","sequence":"additional","affiliation":[{"name":"Center for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Bettinger","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Center, BC Children\u2019s Hospital Research Institute"},{"name":"Division of Infectious Diseases, Department of Paediatrics, BC Children\u2019s Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Drouin","sequence":"additional","affiliation":[{"name":"Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine"},{"name":"Department of Social and Preventive Medicine, School of Public Health, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E.","family":"Embree","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, IWK Health Center, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Moore Hepburn","sequence":"additional","affiliation":[{"name":"Division of Paediatric Medicine, Hospital for Sick Children, Toronto, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tajdin","family":"Jadavji","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases, Alberta Children\u2019s Hospital, University of Calgary, Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kescha","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupeena","family":"Purewal","sequence":"additional","affiliation":[{"name":"Division of Paediatric Infectious Diseases, Jim Pattison Children\u2019s Hospital, Saskatchewan Health Authority, Saskatoon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Center, BC Children\u2019s Hospital Research Institute"},{"name":"Division of Infectious Diseases, Department of Paediatrics, BC Children\u2019s Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sauv\u00e9","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Vaccine Evaluation Center, BC Children\u2019s Hospital Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina A.","family":"Top","sequence":"additional","affiliation":[{"name":"Division of Paediatric Medicine, Hospital for Sick Children, Toronto, Ontario"},{"name":"Department of Pediatrics, University of Alberta, Edmonton, Alberta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Centre Hospitalier Universitaire Sainte-Justine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Papenburg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Infectious Diseases, Montreal Children\u2019s Hospital, McGill University, Montreal, Quebec, Canada"},{"name":"Division of Microbiology, Department of Clinical Laboratory Medicine, McGill University Health Centre"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun K.","family":"Morris","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine"},{"name":"Department of Pediatrics, Faculty of Medicine, University of Toronto"},{"name":"Division of Clinical Public Health and Centre for Vaccine Preventable Diseases, Dalla Lana School of Public Health, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for members of the Canadian Immunization Monitoring Program, ACTive (IMPACT)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"R1-20250924","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1093\/cid\/ciaa556","article-title":"SARS-CoV-2 (COVID-19): what do we know about children? A systematic review.","volume":"71","author":"Mehta","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R2-20250924","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(21)02867-1","article-title":"Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.","volume":"399","year":"2022","journal-title":"Lancet (London, England)"},{"key":"R3-20250924","doi-asserted-by":"crossref","first-page":"e2111182","DOI":"10.1001\/jamanetworkopen.2021.11182","article-title":"Underlying medical conditions associated with severe COVID-19 illness among children.","volume":"4","author":"Kompaniyets","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R4-20250924","doi-asserted-by":"crossref","first-page":"e1004086","DOI":"10.1371\/journal.pmed.1004086","article-title":"Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study.","volume":"20","author":"Turtle","year":"2023","journal-title":"PLoS Med"},{"key":"R5-20250924","first-page":"100337","article-title":"Risk factors for severe COVID-19 in hospitalized children in Canada: a national prospective study from March 2020-May 2021.","volume":"15","author":"Farrar","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"R6-20250924","doi-asserted-by":"crossref","first-page":"e001440","DOI":"10.1136\/bmjpo-2022-001440","article-title":"Risk factors for severe PCR-positive SARS-CoV-2 infection in hospitalised children.","volume":"6","author":"Schober","year":"2022","journal-title":"BMJ Paediatr Open"},{"key":"R7-20250924","doi-asserted-by":"crossref","first-page":"574","DOI":"10.15585\/mmwr.mm7116e1","article-title":"Hospitalizations of children aged 5-11 years with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022.","volume":"71","author":"Shi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R8-20250924","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.eclinm.2022.101287","article-title":"Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: a systematic review and individual patient meta-analysis.","volume":"44","author":"Harwood","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R9-20250924","doi-asserted-by":"crossref","first-page":"e29572","DOI":"10.1002\/pbc.29572","article-title":"Clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients in the province of Quebec.","volume":"69","author":"Ilinca","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20250924","doi-asserted-by":"crossref","first-page":"1900562","DOI":"10.2807\/1560-7917.ES.2020.25.25.1900562","article-title":"Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia.","volume":"25","author":"Top","year":"2020","journal-title":"Euro Surveill"},{"key":"R11-20250924","doi-asserted-by":"crossref","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","article-title":"GISAID: Global initiative on sharing all influenza data \u2013 from vision to reality.","volume":"22","author":"Shu","year":"2017","journal-title":"Euro Surveill."},{"key":"R12-20250924","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research.","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R13-20250924","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jpids\/piy101","article-title":"Clinical features and outcomes of immunocompromised children hospitalized with laboratory-confirmed influenza in the United States, 2011-2015.","volume":"8","author":"Collins","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R14-20250924","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/irv.12939","article-title":"Influenza hospitalizations in Australian children 2010-2019: the impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness.","volume":"16","author":"Norman","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"key":"R15-20250924","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.cmi.2023.04.001","article-title":"Outcomes of immunocompromised children hospitalized for influenza, 2010-2021, the Canadian Immunization Monitoring Program Active (IMPACT).","volume":"29","author":"Schober","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"R16-20250924","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3201\/eid2608.191493","article-title":"Analysis of marketscan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States.","volume":"26","author":"Patel","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"R17-20250924","doi-asserted-by":"crossref","first-page":"e0272648","DOI":"10.1371\/journal.pone.0272648","article-title":"Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada.","volume":"17","author":"Piche-Renaud","year":"2022","journal-title":"PLoS One"},{"key":"R18-20250924","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study.","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"R19-20250924","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia.","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"R20-20250924","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-021-04345-x","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults.","volume":"602","author":"Yoshida","year":"2022","journal-title":"Nature"},{"key":"R21-20250924","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12879-018-3002-3","article-title":"Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study.","volume":"18","author":"Chatzis","year":"2018","journal-title":"BMC Infect Dis"},{"key":"R22-20250924","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/INF.0000000000003043","article-title":"Risk factors for severe COVID-19 in children.","volume":"40","author":"Graff","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20250924","doi-asserted-by":"crossref","first-page":"e2021053418","DOI":"10.1542\/peds.2021-053418","article-title":"Risk factors for severe COVID-19 in children.","volume":"149","author":"Woodruff","year":"2022","journal-title":"Pediatrics"},{"key":"R24-20250924","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2022.09.005","article-title":"Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19.","volume":"150","author":"Abolhassani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R25-20250924","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/joim.13628","article-title":"Human genetic and immunological determinants of SARS-CoV-2 and Epstein-Barr virus diseases in childhood: insightful contrasts.","volume":"294","author":"Pan-Hammarstr\u00f6m","year":"2023","journal-title":"J Intern Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:01:36Z","timestamp":1758744096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004856","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}